innoVitro is a biotech company with core competence in the measurement of cellular forces, in particular of stem cell derived cardiomyocytes.
Cardiovascular diseases are the most common cause of death in the western world. Although mortality is steadily decreasing due to the continuous improvement of emergency medical care, late effects lead to a loss of life quality and high follow-up costs for the health care system. These late effects can be treated by medications with a strength-enhancing effect, which can significantly improve the quality of life of those affected. In the development and characterization of these drugs, the pharmaceutical industry has been dependent on animal experiments, which not only cost a great deal of money but also raise ethical concerns among public opinion.
innoVitro is working on the establishment of an in vitro cardiac muscle model based on the FLEXcyte technology and human cardiac muscle cells.
The model is intended to be an alternative to animal experiments which will enable the qualitative and quantitative determination of substance effects on the contractility of myocardial cells. By using human stem cell derived cardiomyocytes, common issues with the translatability of pharmacological results from animal models to human physiology are avoided already in the preclinical phase of drug development.
Dr. rer. nat. Dipl. Ing. (FH) Matthias Goßmann holds a degree in biotechnology and a doctorate in chemistry. Since 2008, he has been working on the development of the CellDrum technology. He gained 3.5 years of experience as a scientist in stem cell industry (Axiogenesis AG) before turning to the field of business development as one of the two founders of innoVitro.
The second founder of innoVitro, Dipl. Ing. (FH) Peter Linder MSc., has already contributed to the first development steps of the CellDrum technology, the predecessor of the FLEXcyte, in his diploma thesis in the field of biomedical technology. His further career includes a Master of Science in cooperation with the University Hospital of Cologne as well as project work in the field of aerospace technology. Besides his current doctorate on III. Physical Institute B at RWTH Aachen University, he is responsible at innoVitro for hardware and software development as well as laboratory management.
The team has been working together successfully for many years and complements each other excellently in its personal and professional qualities.
Since 2019 Dr. rer. nat. Dipl. Biol. Bettina Lickiss is the third member of the innoVitro team and responsible for marketing solutions and business development. Bettina holds a doctorate degree in neurobiology and gained 5 years of experience in the stem cell biotech industry and field of human iPSC-derived cardiomyocytes before working for innoVitro.
Nanion Technologies, one of the world’s leading providers of cell-based assays, collaborates with innoVitro in the development of the FLEXcyte 96 screening platform for cellular force measurement. Nanion will take over the production and distribution of the FLEXcyte 96 device in close cooperation with innoVitro.
The team of innoVitro is a member of the HESI Cardiac Safety Technical Committee, a consortium of pharmaceutical companies, technology providers, regulatory authorities and universities where new technologies are evaluated.
"We were very pleased with our choice to engage innoVitro’s contractility service. The studies using human iPSC-derived cardiomyocytes were tailored to our needs to provide results comparable to already existing (in house) data and the fast execution followed by a comprehensive study report completed the service perfectly."Nina Glaser,
Head of Early Safety Electrophysiology,
Merck Healthcare KGaA